EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Semi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies: Clinical Implications

Sorana Caterina Anton, Alin Horatiu Nedelcu iD, Victor Ianole iD, Carmen Anton iD, Mihai Danciu iD, Ionela Daniela Morariu iD, Ancuța Lupu iD, Gabriel Dascalescu iD, Vasile Valeriu Lupu iD, Anton Knieling, Delia Nicolaiciuc, Alin Ciobica und 6 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27041729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Sorana Caterina Anton und 17 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: BRCA1 Protein, Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aggressive breast cancer subtypes, such as triple-negative breast cancer (TNBC) and tumors in BRCA1 germline mutation carriers, present significant clinical challenges. The role of BRCA1 protein expression, assessed via immunohistochemistry (IHC), in defining the biology of these high-risk tumors remains to be fully elucidated. We performed a semi-quantitative IHC analysis of BRCA1 protein expression in a targeted cohort of 100 invasive breast carcinomas, enriched for TNBC (88%) and BRCA1 mutation carriers (34%). A validated monoclonal antibody and a composite scoring system (0–9) were employed, with an optimal cut-off defined by ROC analysis. Associations with clinicopathological parameters and p16 expression were evaluated. Low BRCA1 expression was strongly associated with an aggressive phenotype, including invasive ductal histology, hormone receptor negativity, and the TNBC subtype (all p < 0.001). Tumors with BRCA1 loss exhibited a more pro-tumorigenic microenvironment, characterized by higher rates of necrosis (p = 0.014) and denser mononuclear infiltrates (p = 0.019). A significant inverse correlation with p16 overexpression was identified (p = 0.030). Our findings demonstrate that BRCA1 protein loss delineates a distinct aggressive tumor biology within high-risk breast cancers. We emphasize that BRCA1 IHC is a complementary biomarker and cannot supplant germline genetic testing for clinical decision-making regarding targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA1 ProteinTriple Negative Breast NeoplasmsBreast NeoplasmsHumansFemaleImmunohistochemistryBiomarkers, TumorMiddle AgedGerm-Line MutationAdultTumor MicroenvironmentCyclin-Dependent Kinase Inhibitor p16

Stichwörter der Autor:innen

BRCA1biomarkerimmunohistochemistrytriple-negative breast cancertumor microenvironment

Substanzen

BRCA1 ProteinBRCA1 protein, humanBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16

Autor:innen und Institutionen

  • Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Department of Pathology, "Prof. Dr. Nicolae Oblu" Emergency Clinical Hospital, 700309 Iasi, Romania.
  • Department of Pathology, "Saint Spiridon" County Hospital, 700111 Iasi, Romania.
  • Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Department of Biology, Faculty of Biology, Alexandru Ioan Cuza University of Iasi, B-Dul Carol I, No. 11, 700506 Iasi, Romania.
  • "Ioan Haulica" Institute, Apollonia University, 700511 Iasi, Romania.

ORCID-Profile: Alin Horatiu Nedelcu, Victor Ianole, Carmen Anton, Mihai Danciu, Ionela Daniela Morariu, Ancuța Lupu, Gabriel Dascalescu, Vasile Valeriu Lupu, Mihaela Grigore, Emil Anton

Zitieren

APA

Anton, S. C., Nedelcu, A. H., Ianole, V., Anton, C., Danciu, M., Morariu, I. D., Lupu, A., Dascalescu, G., Lupu, V. V., Knieling, A., Nicolaiciuc, D., Ciobica, A., Chivasuta, E. A., Tirnovanu, M., Dondiuc, I., Ilea, C., Grigore, M., & Anton, E. (2026). Semi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies: Clinical Implications. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041729

Vancouver

Anton SC, Nedelcu AH, Ianole V, Anton C, Danciu M, Morariu ID, et al. Semi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies: Clinical Implications. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041729

BibTeX
@article{Anton2026,
  author = {Anton, Sorana Caterina and Nedelcu, Alin Horatiu and Ianole, Victor and Anton, Carmen and Danciu, Mihai and Morariu, Ionela Daniela and Lupu, Ancuța and Dascalescu, Gabriel and Lupu, Vasile Valeriu and Knieling, Anton and Nicolaiciuc, Delia and Ciobica, Alin and Chivasuta, Elena Andreea and Tirnovanu, Mihaela and Dondiuc, Iurie and Ilea, Ciprian and Grigore, Mihaela and Anton, Emil},
  title = {Semi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies: Clinical Implications},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27041729}
}
Kostenlos starten →